Clinical Report: Is Intravenous Methylprednisolone Efficacious for Visual Complications of GCA?

Overview

A population-based study evaluated the efficacy of intravenous methylprednisolone (IVMP) for visual complications in giant cell arteritis (GCA). This retrospective study analyzed data from 419 patients in Sweden with biopsy-confirmed GCA over a 15-year period, comparing those treated with IVMP against those receiving only oral glucocorticoids (OGC). The study found no significant improvement in visual acuity outcomes with IVMP compared to OGC.

Background

Giant cell arteritis (GCA) can lead to serious visual complications, affecting up to half of patients. Prompt treatment is critical to prevent vision loss, and current guidelines recommend IVMP for patients with visual ischemia, as stated in the 2021 ACR/VF Guideline for Management of Giant Cell Arteritis and Takayasu Artheritis. Understanding the effectiveness of IVMP compared to traditional oral glucocorticoids is essential for optimizing patient outcomes.

Data Highlights

Key Findings

• No significant difference in overall survival or comorbidities between IVMP and OGC groups.
• IVMP did not significantly improve visual acuity compared to OGC alone.
• 20% of patients on IVMP experienced meaningful visual acuity improvement.
• Patients over 80 years had a higher incidence of adverse effects with IVMP.
• IVMP was associated with a higher risk of new-onset diabetes mellitus (11.7% vs. 4.9% for OGC).

Clinical Implications

The findings indicate that IVMP may not provide significant benefits in visual acuity compared to oral glucocorticoids. Clinicians should consider the risk of adverse effects, particularly in older patients, when evaluating treatment options.

Conclusion

This study indicates that IVMP does not demonstrate a clear advantage over oral glucocorticoids in improving visual outcomes for patients with GCA.

Related Resources & Content

1. Retinal Physician, Steroid Implants in the Diabetic Macular Edema Treatment Paradigm, 2019
2. Ophthalmology Management, Getting Uveitis Under Control –Quickly, 2010
3. Retinal Physician, Treating Macular Edema, 2010
4. Frontiers in Medicine, A combined model of BCVA, TRAb, and NLR predicts response to intravenous methylprednisolone in dysthyroid optic neuropathy, 2026
5. Vasculitis Foundation, 2021 ACR/VF Guideline for Management of Giant Cell Arteritis and Takayasu Artheritis
6. Annals of the Rheumatic Diseases, 2018 Update of the EULAR recommendations for the management of large vessel vasculitis
7. RMD Open, Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis
8. PMC, The use of intravenous methylprednisolone in giant cell arteritis: a population-based study
9. https://www.vasculitisfoundation.org/wp-content/uploads/2024/01/2021-ACR-VF-Guideline-for-Management-of-Giant-Cell-Arteritis-and-Takayasu-Artheritis.pdf
10. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis | Annals of the Rheumatic Diseases
11. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis | RMD Open
12. The use of intravenous methylprednisolone in giant cell arteritis: a population-based study - PMC